🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against drug-resistant strains of the infection, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating around the world, with data suggesting in excess of 82 million new cases annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the very limited therapeutic options at this time.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, gained clearance in the same week. This medication, which is employed against UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a unique collaborative effort for medication research. The charitable organization GARDP worked alongside the drug firm Innoviva to see it through.

“This authorization marks a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

Based on data detailed in a major medical journal, the new drug successfully treated over nine in ten of cases of the STI. This establishes an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research included nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to register and commercialise the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. Access to a single-dose, oral treatment such as this is described as a "critical tool" for public health efforts. This is viewed as crucial to lessen the impact of the infection for patients and to halt the transmission of highly drug-resistant gonorrhoea globally.